The High Throughput Biomedicine Unit (HTB) provides high throughput screening approaches of many types:
- Drug Sensitivity and Resistance testing (DSRT assay). A set of clinically relevant and targeted bioactive compounds are tested in a dose response series against patient-derived primary cancer cells or cell-lines, after which responses, typically in the form of DSS:s are calculated for each drug. The standard DSRT assay consists, to date, of 527 drugs in 5 concentrations, on 8 384-well plates. The standard readout in an DSRT assay is cell viability and cell death, but microscopic readouts are also offered. For more detailed information see: Pemovska T. et al. 2013; Pemovska T. et al. 2015.
- siRNA screening
- Cell-based and biochemical screens using targeted or large chemically diverse libraries
- Molecular probe discovery
- Biological profiling using libraries of known bioactives
- Drug repositioning
- Personalized medicine screening (drug resistance and sensitivity) using approved and investigational drugs
- We offer a wide set of chemicals and chemical libraries for screening, that can be cherry picked or combined according to your interests and needs.
- A genome-wide siRNA library from Ambion is also available for siRNA screening, both for large fullgenome screens and for more focused subset screens.
In addition to performing and assisting with the screening, the staff of the HTB can consult and assist researchers on various other aspects surrounding RNAi screening, chemical biology and drug discovery, such as assay development and optimization as well as advice on screening and drug discovery strategies.
We also have a network of chemoinformaticians, medicinal chemists and other drug development experts.
More comprehensive information about the High Throughput Biomedicine unit can be found from the FIMM website: https://www.fimm.fi/en/services/technology-centre/high-throughput-biomedicine